HEMATOLOGIC MALIGNANCIES

This study provides access to unlicensed, frozen cord blood units for transplant in children and adults with blood cancers and other serious blood disorders. Researchers aim to track how well patients' immune systems recover after transplant and monitor survival rates and complic…

This is the first human study of an experimental drug called INCA036873, designed to test its safety and side effects in people with advanced cancers. The trial will enroll 280 adults with specific types of solid tumors or blood cancers that have worsened despite prior treatments…

This study is testing a personalized approach to stem cell transplants for adults with blood cancers like leukemia and lymphoma. Doctors will adjust the doses of chemotherapy and radiation given before the transplant based on each patient's specific health and disease risks. The …

This study is testing whether an inhaled experimental drug called PUL-042 can reduce the severity of lung infections in a very vulnerable group: adults with blood cancers or who have received a stem cell transplant. These patients have weakened immune systems and are at high risk…

This study aims to find the safest, most effective dose of an immune-suppressing drug (cyclophosphamide) given after a stem cell transplant. It involves 26 patients aged 65 and older with blood cancers. Researchers are testing whether a lower dose can reduce side effects while st…

This study allows patients with blood cancers who are already benefiting from tafasitamab treatment in a previous trial to continue receiving it. It aims to monitor the safety of this extended therapy for up to 25 participants. The study is specifically for patients whose disease…

This early-phase study is testing whether a modified immune cell infusion given after a stem cell transplant can help prevent cancer recurrence in high-risk blood cancer patients. Researchers will give 38 participants processed immune cells from their donors to find the safest do…

This study is tracking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in patients who were already receiving it in previous Merck trials. It will follow 3,500 people with various solid tumors or blood cancers to see how they do over an extended…

This study is testing a new combination of drugs designed to prevent a dangerous complication called graft-versus-host disease (GVHD) after a bone marrow transplant. The goal is to see if this approach is safe and effective for people living with HIV who have blood cancers that c…

This study is testing a new approach for adults with aggressive blood cancers that are hard to cure. It combines two powerful treatments—a bone marrow transplant from a partially matched donor and genetically modified immune cells (CAR-T cells)—given at the same time. The goal is…

This study is testing whether a different medication approach can better prevent chronic graft-versus-host disease (GVHD) after stem cell transplants for blood cancers. Researchers will compare a new strategy using the drug ruxolitinib against the standard prevention method. The …

This is the first time a new drug called RJK-RT2831 is being tested in people. The main goal is to find a safe dose and check for side effects in about 70 adults with advanced blood cancers like leukemia that have come back or haven't responded to standard treatments. Researchers…

This program provides expanded access to a special two-part stem cell transplant for patients with high-risk blood cancers or genetic disorders who cannot find a perfectly matched donor. It uses stem cells from a partially matched family member to provide a temporary 'bridge' whi…

This is the first study in people to test a new cancer drug called IM-1021. The main goals are to find a safe dose and see how the body processes the drug in adults with advanced solid tumors or blood cancers that have not responded to standard treatments. Researchers will also l…

This study is testing whether giving patients antibody replacement therapy (IVIG) can prevent serious bacterial infections after they receive a powerful cancer treatment called CD19 CAR-T cell therapy. CAR-T therapy can leave patients with low antibody levels, making them vulnera…

This study is testing a new drug called SLS009 for people with advanced blood cancers that have come back or stopped responding to treatment, and for newly diagnosed patients with high-risk forms of leukemia. The main goals are to find a safe dose and see if the drug, given alone…

This study is testing an oral drug called nemtabrutinib in people with several types of advanced blood cancers that have come back or stopped responding to other treatments. It aims to find a safe and effective dose and see how well the drug shrinks tumors and controls the diseas…

This study is testing a second stem cell transplant using donated umbilical cord blood for patients whose high-risk blood cancer has returned after their first transplant. The goal is to see if using a less intense pre-transplant treatment can help control the disease and improve…

This study is testing whether combining two drugs, ICP-248 and orelabrutinib, is safe and effective for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who haven't received treatment yet. Researchers will enroll about 226 adults to see how w…

This study is testing a digital health program designed to help patients and their family caregivers during and after outpatient CAR-T therapy, a treatment for blood cancers. The program uses remote monitoring to track patient symptoms and caregiver stress. The goal is to see if …

This study aims to understand how a specific protein called CD56 appears in different types of blood cancers. Researchers will measure CD56 levels in 38 newly diagnosed patients to see if its presence is linked to how the disease progresses. The goal is to gather knowledge that m…

This study is testing a new decision support tool called PRIME to see if it helps older adults with blood cancers and their doctors make initial treatment choices that better reflect what matters most to the patient. The tool asks patients about their treatment priorities and cre…

This early-stage study aims to understand how the cancer drug pralatrexate is processed by the body in people with varying degrees of liver impairment. It will involve about 24 adults with advanced solid tumors or blood cancers. The main goal is to measure drug levels in the bloo…

This study aims to understand how certain leukemia and lymphoma drugs, called BTK inhibitors, affect the heart and may increase the risk of dangerous irregular heartbeats. Researchers will monitor 135 adults who are already taking or planning to start these drugs, using heart tes…

This study aims to create the first detailed, long-term record of lymphoma patients in Malawi. Researchers will enroll 800 people with suspected lymphoma, perform standard biopsies for accurate diagnosis, and follow their health for up to five years. The goal is to gather reliabl…